Clinical trials: Chronic Liver Disease and Cirrhosis, active
Steatohepatitis, Nonalcoholic, Steatosis of Liver
Ketogenic Diet in MASLD-related cACLD
The investigators hypothesize that very low ketogenic diet could represent a new therapeutic option in the management of patients with MASLD and cACLD.
- Conditions
- Steatohepatitis, Nonalcoholic, Steatosis of Liver, Cirrhosis, Liver
- Trial name
- NCT06537466
- Testing
- Mediterranean diet, Very Low Ketogenic Diet
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- University of Palermo
Autoimmune Hepatitis, Primary Sclerosing Cholangitis
Liver-gut Axis Study Through Identification of Liver Disease-specific Microbiome
In this study, we aim to identify gut microbiomes specific to patients with chronic refractory liver disease and to conduct a gut-liver axis study on the pathogenesis and disease progression.
- Conditions
- Autoimmune Hepatitis, Primary Sclerosing Cholangitis, Non-Alcoholic Fatty Liver Disease, Liver Abscess
- Trial name
- LGAS (NCT06519162)
- Where
- South Korea
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Chungnam National University Hospital
Autoimmune Liver Disease, Liver Transplant Disorder
A Study of SIPLIZUMAB in AILD and LT Patients
There is a significant unmet need for safe and effective therapeutic approaches to prevent immune-mediated graft injury and its complications in liver transplant (LT) recipients with autoimmune liver disease (AILD) including…
- Conditions
- Autoimmune Liver Disease, Liver Transplant Disorder, Autoimmune Hepatitis, Primary Sclerosing Cholangitis
- Trial name
- SET-SAIL (NCT06455280)
- Testing
- Siplizumab
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Elizabeth C. Verna
Chronic Liver Disease (CLD), Fibrosis of Liver
Assessing Signatures for Fibrosis Detection in Chronic Liver Disease: A Step Beyond Conventional Biomarkers
Morbidity and mortality of CLD is driven by the extent of liver fibrosis, characterized by scar formation and disruption of the normal liver architecture. HSCs play a central role in liver fibrosis development.
- Trial name
- NCT07359742
- Testing
- Blood draw for biomarkers
- Where
- Belgium
- Volunteers
- 110 people
- Sponsor
- Universitair Ziekenhuis Brussel
Hepatocellular Carcinoma, Liver Cirrhosis
Prospective Evaluation of Hepatocellular Carcinoma Surveillance in At-Risk Patients (Screening HCC)
This prospective multicenter observational study evaluates the performance of a structured hepatocellular carcinoma (HCC) surveillance program in patients at increased risk of developing liver cancer.
- Conditions
- Hepatocellular Carcinoma, Liver Cirrhosis, Chronic Hepatitis B, Metabolic Dysfunction-Associated Steatotic Liver Disease
- Trial name
- Screening HCC (NCT07764835)
- Volunteers
- 300 people
- Sponsor
- D'Or Institute for Research and Education
Chronic Liver Disease, Cirrhosis
An Observational Study of Patients With Chronic Liver Disease
TARGET-Liver Disease (TARGET-LD) is an observational research study to conduct a comprehensive review of outcomes for patients with chronic liver disease (CLD).
- Trial name
- NCT05744713
- Testing
- Observational
- Where
- 10 sites in United States
- Volunteers
- 500,000 people
- Sponsor
- Target PharmaSolutions, Inc.
Hepatocellular Carcinoma, Liver Cirrhosis
naVIGation Invitations Liver surveillANce upTake
This study aims to evaluate the efficacy of Patient Navigators and mailed surveillance invitations on attendance of Hepatocellular Carcinoma (HCC) ultrasound surveillance appointments.
- Conditions
- Hepatocellular Carcinoma, Liver Cirrhosis, Chronic Hep B
- Trial name
- VIGILANT (NCT06635694)
- Where
- United Kingdom
- Volunteers
- 652 people
- Sponsor
- Imperial College London
HEPATITIS B CHRONIC, Cirrhosis, Liver
Effect of Babao Dan Capsule Combined With Antiviral Therapy on the Incidence of Hepatocellular Carcinoma in Patients With Hepatitis B-related Cirrhosis
This study aims to establish a prospective, multicenter, randomized, double-blind, placebo-controlled parallel-group clinical trial cohort.
- Conditions
- HEPATITIS B CHRONIC, Cirrhosis, Liver, Hepatocellular Carcinoma (HCC)
- Trial name
- NCT07544121
- Testing
- Babao Dan Capsule, Babao Dan Capsule simulant
- Volunteers
- 1,034 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Liver Disease; Alcohol-Related, Cirrhosis
Intestinal Microbiota Transplant in Alcohol-Associated Liver Disease
The purpose of this research study is to test the safety, tolerability, and effectiveness of the capsules that contain bacteria from healthy individuals when used to treat alcohol craving and drinking.
- Conditions
- Liver Disease; Alcohol-Related, Cirrhosis, Alcohol Use Disorder
- Trial name
- IMPACT (NCT05548452)
- Testing
- Intestinal Microbiota Transplant (IMT) Capsules
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- Virginia Commonwealth University
Non-alcoholic Fatty Liver Disease (NAFLD), Non-alcoholic Steatohepatitis (NASH)
Simultaneous Quantification of Liver Fat Content, Fatty Acid Composition, and Fibrosis Using Spin-lock MRI for Steatohepatitis Assessment
Non-alcoholic fatty liver disease is a major health problem worldwide. It includes simple steatosis and NASH which has inflammation in the liver, with or without fibrosis.
- Trial name
- NCT05384652
- Where
- Hong Kong
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Chinese University of Hong Kong
Cirrhosis, Ascites Hepatic
Using Bedside Ultrasound to Understand Fluid Management in Patients With Chronic Liver Disease
The goal of this observational study is to see if repeated bedside ultrasound measurements of the lungs and abdomen as well as a blood vessel in the neck can be done in patients with advanced liver disease and ascites (fluid in…
- Conditions
- Cirrhosis, Ascites Hepatic, Fluid Balance
- Trial name
- POCUS-C (NCT07810855)
- Testing
- Ultrasound measurement, Blood draw for the laboratory assessment
- Volunteers
- 100 people
- Sponsor
- Royal Free Hospital NHS Foundation Trust
Acute-on-Chronic Liver Failure (ACLF), Liver Cirrhosis
Evaluating Novel Scoring Systems to Predict Outcomes in Acute-on-Chronic Liver Failure
Acute-on-chronic liver failure (ACLF) is a serious condition where a patient with long-term liver disease suddenly experiences severe liver worsening and failure of other organ systems, such as the kidneys or lungs.
- Conditions
- Acute-on-Chronic Liver Failure (ACLF), Liver Cirrhosis, End Stage Liver Disease
- Trial name
- NCT07734896
- Volunteers
- 100 people
- Sponsor
- Assiut University
Cirrhosis, Microplastics
Microplastics, Cirrhosis and Portal Hypertension
Cirrhosis and portal hypertension are associated with an hyperdynamic circulation and hepatic inflammation, leading to complications like ascites, variceal bleeding, acute kidney injury, and higher infection risk.
- Conditions
- Cirrhosis, Microplastics, Portal Hypertension Related to Cirrhosis, Nanoplastics
- Trial name
- NCT07280390
- Testing
- Assessment of microplastics in tissue
- Where
- 2 sites in India
- Volunteers
- 30 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Liver Fibrosis
Prediction of Significant Liver Fibrosis
The deep learning method based on convolutional neural network (CNN) was used to extract the relevant features of liver fibrosis classification from the multi-modal information of digital pathological sections, clinical…
- Trial name
- PSLF (NCT06509230)
- Where
- China
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- Huang Haijun
Chronic Liver Disease, Alcohol Use Disorder
Nottingham Community Liver Biomarkers Cohort
Deaths due to advanced liver scarring (liver cirrhosis) continue to increase, and liver disease is now the 3rd leading cause of premature death in the United Kingdom.
- Conditions
- Chronic Liver Disease, Alcohol Use Disorder, Type 2 Diabetes, Persistently Elevated ALT
- Trial name
- NCT02037867
- Testing
- Fibrosis Biomarkers
- Where
- United Kingdom
- Volunteers
- 2,000 people
- Sponsor
- University of Nottingham
Chronic Liver Disease
Prognosis Value of Non-invasive Methods for the Diagnosis of Chronic Liver Disease
The aim of this retrospective and prospective study is to evaluate the 20-year prognosis value of non-invasive methods for the diagnosis of chronic liver disease for predicting survival and complications of cirrhosis.
- Trial name
- PVNIM (NCT02060565)
- Where
- France
- Volunteers
- 10,000 people
- Sponsor
- Association HGE CHU Bordeaux Sud
Fibrosis, Liver
Screening for Chronic Liver Diseases in General Population
Improving the care of patients with liver diseases in primary care and will allow patients with chronic liver disease to benefit from a course appropriate care.
- Trial name
- HEPGEN (NCT06366425)
- Testing
- Blood sample then fibroscan
- Where
- France
- Volunteers
- 260 people
- Sponsor
- University Hospital, Montpellier
Steatotic Liver Disease, Liver Fibrosis Progression in Chronic Liver Disease
Interventional AI-Human Collaboration for Steatotic Liver Disease Screening
Steatotic liver disease (SLD) is one of the most prevalent chronic liver diseases worldwide, affecting nearly 30% of the global population and projected to exceed 55% by 2040.
- Conditions
- Steatotic Liver Disease, Liver Fibrosis Progression in Chronic Liver Disease, Liver Steatosis, Liver Fibrosis
- Trial name
- NCT07613827
- Testing
- AI-human collaboration for SLD screening
- Where
- China
- Volunteers
- 7,969 people, healthy volunteers welcome
- Sponsor
- Shengjing Hospital
Chronic Liver Disease and Cirrhosis
Non-invasive Methods for Predicting Decompensation of Chronic Liver Disease
Preliminary studies have suggested that non-invasive methods can not only be applied to CSPH but also to predict the risk of decompensation in cirrhosis.
- Trial name
- NCT06741904
- Where
- China
- Volunteers
- 2,334 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Cirrhosis, End Stage Liver DIsease
HepHospital: A Pilot Trial of a Hepatology Home Hospital Intervention for Patients With Advanced Liver Disease
This research study is evaluating a program that entails a healthcare at home intervention for people with advanced liver disease.
- Conditions
- Cirrhosis, End Stage Liver DIsease, Liver Cirrhosis, Liver Disease Chronic
- Trial name
- NCT05205954
- Testing
- Hepatology Home Hospital
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Massachusetts General Hospital